Psychedelic Spotlight
  • News
  • Culture
  • Business
    • Business
    • News
    • Editorial
    • Stock Reports
    • Videos
    • Interviews
  • Research
  • Policy
  • PSPACE
  • Media
    • Media
    • Podcast
    • Videos
  • Advertise With us
    • Advertise With Us
    • Contact Us
    • About
  • Media Kit
  • Search
  • Menu Menu
Home1 / Psychedelic Spotlight News2 / Business3 / Stock Reports4

Psychedelic Business Spotlight – May 27

byGreg GilmanonMay 27, 2022
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn

This week in psychedelic business news: New patents; another Health Canada SAP Approval; and legal psilocybin rules for Oregon.

CB Therapeutics Granted New Psychedelic Patent

This week in psychedelic business news, CB Therapeutics has obtained a patent covering the use of microorganisms to produce tryptamines and their analogs, such as psilocybin and various other molecules found in psychedelic mushrooms. CEO Sher Ali Butt says this patented process to produce these molecules is “more environmentally sustainable” than other industry methods, which can create significant amounts of toxic waste, CO2 and other byproducts that negatively impact the environment. CB Therapeutics’ cellular agriculture platform enables the conversion of cheap feedstocks into high-value compounds, resulting in a scalable and eco-conscious supply chain, carried out by precision fermentation.

Braxia Scientific Gets Health Canada SAP Approval to Provide Psilocybin-Assisted Therapy for Depression in Ontario

Braxia Scientific (CSE: BRAX) (OTC: BRAXF) (FWB: 4960) is the latest psychedelic company to score approval from Health Canada's Special Access Program to treat a patient with psilocybin-assisted psychotherapy for Major Depressive Disorder in Ontario. “To our knowledge, this is the first Health Canada SAP approval for psilocybin-assisted therapy for a person with Major Depressive Disorder in Ontario,” said the company's Chief Medical and Scientific Officer Dr. Joshua Rosenblat. “Health Canada was very responsive to this request, promptly providing the Letter of Authorization. This rapid approval stands in contrast  to the previously required Section 56 exemptions that could take years to fully process. Allowing use of the SAP will be incredibly beneficial for patients in need of this treatment that are unable to receive it through psychedelic clinical trials.” Although this is Braxia Scientific's first psilocybin-assisted therapy treatment approval through SAP, the company was first to receive Health Canada approval for a multi-dose psilocybin-assisted therapy clinical trial in July 2021, dosing its first participant in November 2021, and since providing psilocybin-assisted therapy to 16 individuals living with depression.

Ojai Energetics Offers Portfolio of Psychedelic Patents at Davos

The World Economic Forum in Davos, Switzerland just wrapped up its first-ever showcase of the psychedelic industry via The House of Psychedelics, which featured almost 40 sessions and speakers, including researchers, entrepreneurs, investors, and even shamans. Among those companies was Ojai Energetics, who went to offer up a psychedelic IP portfolio of LSD, ketamine, and psilocybin/psilocin assets for sale. “OE has built one of the most robust psychedelics patent portfolios in the world,” said Sr. VP of Business Development, Andre Bourque. “Our patents cover drug delivery platform composition of matter for all psychedelic drugs, such as tryptamine class compounds (LSD, psilocybin, DMT), phenethylamine class compounds (mescaline, MDMA), and ketamine to name a few.” Three in particular, he said, “outperform what's available on the market” and the company is “seeking to add them to the right portfolio for well-intentioned therapeutic research and development.”

Oregon Adopts First Set of Rules for Legal Psilocybin

Last, but not least in this week's psychedelic business news, Oregon Health Authority (OHA) adopted the state’s first set of administrative rules regarding psilocybin products, testing, and training programs. When the state’s trailblazing therapeutic psilocybin program, authorized by the Oregon Psilocybin Services Act, commences this coming January, licensed manufacturers will only be allowed to cultivate or possess one specific fungi species: psilocybe cubensis. Additionally, psilocybin products are limited to those products that can be consumed orally. Read over the OHA’s full first batch of finalized rules here.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *

Related News

NaturoMed Therapeutics

Company Spotlight: NaturoMed Therapeutics

Business
Canadian organic mushroom company NaturoMed Therapeutics looks to produce psilocybin in Q4 2022
0 Comments
/
July 22, 2022

Oregon Adopts First Set of Rules for Legal Psilocybin

Policy
Oregon Health Authority did not budge on three rules that the public took issue with.
0 Comments
/
May 24, 2022
Maria Sabina

Toronto Psychedelic Exhibition features the Art and History of Psychedelics

Culture
Psychedelic art and history take center stage at Toronto's immersive event entitled 'Psychedelics: The Experiential Exhibition'
0 Comments
/
October 10, 2022

Psychedelic Spotlight is your reliable source for the latest stories in the emerging psychedelics industry, covering breakthrough discoveries, investor news and cultural reform.

Explore

  • About
  • Treatment
  • Advertise With Us
  • News
  • Privacy Policy
  • Terms and Conditions

Resources

  • Conferences
  • Experts
  • Glossary
  • Therapy

Subscribe

           

© 2023 Psychedelic Spotlight. | Owned and operated by PSYC Media Corporation, Inc. a US publicly traded company (OTCPink: PSYC) | All Rights Reserved.
How to Microdose Psilocybin According to Paul Stamets: The Stamets StackShutterstock5 Next-Generation Psychedelics Entering Clinical Trials This YearShutterstock5 Next-Generation Psychedelics Entering Clinical Trials This Year
Scroll to top

Get a roundup of Psychedelic news stories in your inbox

By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.

Hidden
Which list would you like to subscribe to?
Enter your email below to subscribe to Psychedelic News.